دورية أكاديمية
أعرض في EDS

Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands.

التفاصيل البيبلوغرافية
العنوان: Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands.
المؤلفون: Reesink DJ; Department of Urology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands. d.reesink@antoniusziekenhuis.nl., van de Garde EMW; Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein / Utrecht, The Netherlands.; Division Pharmaco Epidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands., van der Nat P; Division Value Based Healthcare, St. Antonius Hospital, Nieuwegein / Utrecht, The Netherlands.; Scientific Center for Quality of Healthcare (IQ Healthcare), Radboud UMC, Nijmegen, The Netherlands., Somford DM; Department of Urology, Canisius Wilhelmina Hospital (CWZ), Nijmegen, The Netherlands., Los M; Department of Oncology, St. Antonius Hospital, Nieuwegein / Utrecht, The Netherlands., Horenblas S; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek (NCI-AVL) Hospital, Amsterdam, The Netherlands., van Melick HHE; Department of Urology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.
مؤلفون مشاركون: Santeon MIBC Study Group
المصدر: World journal of urology [World J Urol] 2022 Jun; Vol. 40 (6), pp. 1469-1479. Date of Electronic Publication: 2022 Apr 10.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 8307716 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-8726 (Electronic) Linking ISSN: 07244983 NLM ISO Abbreviation: World J Urol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Berlin ; New York] : Springer International, 1983-
مواضيع طبية MeSH: Urinary Bladder Neoplasms*/pathology, Cystectomy ; Hospitals ; Humans ; Muscles ; Neoadjuvant Therapy ; Neoplasm Invasiveness ; Netherlands/epidemiology ; Treatment Outcome
مستخلص: Purpose: Population-based studies on treatment patterns in oncology and corresponding clinical outcomes can help identify strategies towards optimal value for patients. This study was performed to describe the variation in treatment patterns and major oncological outcomes for muscle-invasive or metastatic bladder cancer (MIBC/mBC) patients in the Netherlands.
Methods: Patients diagnosed with cT2-4aN0-3M0-1 disease between 2008 and 2016 in seven large teaching hospitals in the Netherlands were included. Baseline characteristics, disease stage, intended and definitive treatment, and oncological outcomes were collected. Patients were categorized based on cTNM-stage: (1) cT2-4aN0M0, (2) cT2-4aN1-3M0 and (3) cT4b and/or M1.
Results: The total study population comprised 1853 patients, of which 1303 patients were diagnosed with cT2-4aN0M0 disease. Overall, curative treatment was intended in 81% (range 74-85%, P value = 0.132). Radical cystectomy (RC) and curative radiotherapy (RTx) ranged between hospitals from 42 to 66% and 13 to 27%, respectively (P value < 0.001). For 334 patients staged cT4b and/or M1, frequencies for palliative therapy and best supportive care (no anti-cancer therapy) ranged between hospitals from 20 to 54% and 44 to 71%, respectively (P value < 0.001). There was no association between hospital site and overall survival (OS) in a univariable and multivariable Cox regression for survival analysis (after adjusting for age and cT-stage), for all three cTNM-groups. Neoadjuvant or induction chemotherapy (NAIC) utilization rates before RC ranged from 8 to 38% (P value < 0.001).
Conclusions: There is large inter-hospital variation in treatment intent in MIBC/mBC patients. This variation does not seem to translate to differences in overall survival rates. There is an ongoing trend of increased use of RC. Utilisation of NAIC is relatively low considering European guideline recommendations.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
References: van der Vlies E, Los M, Stijns PEF, van Hengel M, Blaauw NMS, Bos WJW et al (2020) Preoperative frailty and outcome in patients undergoing radical cystectomy. BJU Int 126:388–395. https://doi.org/10.1111/bju.15132. (PMID: 10.1111/bju.1513232512649)
Schrag D, Mitra N, Xu F, Rabbani F, Bach PB, Herr H et al (2005) Cystectomy for muscle-invasive bladder cancer: Patterns and outcomes of care in the medicare population. Urology 65:1118–1125. https://doi.org/10.1016/j.urology.2004.12.029. (PMID: 10.1016/j.urology.2004.12.02915922428)
Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866. https://doi.org/10.1056/NEJMoa022148. (PMID: 10.1056/NEJMoa02214812944571)
Vale CL (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 48:202–206. https://doi.org/10.1016/j.eururo.2005.04.006. (PMID: 10.1016/j.eururo.2005.04.006)
Griffiths G (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171–2177. https://doi.org/10.1200/JCO.2010.32.3139. (PMID: 10.1200/JCO.2010.32.313921502557)
Moschini M, Mattei A, Cornelius J, Shariat SF, Dell’Oglio P, Zaffuto E et al (2018) Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. World J Urol 36:639–644. https://doi.org/10.1007/s00345-018-2190-1. (PMID: 10.1007/s00345-018-2190-129368231)
Pak S, You D, Jeong IG, Song C, Lee JL, Hong B et al (2019) Induction chemotherapy followed by surgery versus upfront radical cystectomy in patients with clinically node-positive muscle-invasive bladder cancer. Clin Genitourin Cancer. https://doi.org/10.1016/j.clgc.2019.01.001. (PMID: 10.1016/j.clgc.2019.01.00131640913)
Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G et al (2021) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 79:82–104. https://doi.org/10.1016/j.eururo.2020.03.055. (PMID: 10.1016/j.eururo.2020.03.05532360052)
von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608. https://doi.org/10.1200/JCO.2005.07.757. (PMID: 10.1200/JCO.2005.07.75716034041)
De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P et al (2012) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30:191–199. https://doi.org/10.1200/JCO.2011.37.3571. (PMID: 10.1200/JCO.2011.37.357122162575)
Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK et al (2011) A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 12:211–214. https://doi.org/10.1016/s1470-2045(10)70275-8. (PMID: 10.1016/s1470-2045(10)70275-821376284)
Nogué-Aliguer M, Carles J, Arrivi A, Juan O, Alonso L, Font A et al (2003) Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract. Cancer 97:2180–2186. https://doi.org/10.1002/cncr.10990. (PMID: 10.1002/cncr.1099012712469)
Goossens-Laan CA, Visser O, Wouters MWJM, Jansen-Landheer MLEA, Coebergh JWW, Van De Velde CJH et al (2010) Variations in treatment policies and outcome for bladder cancer in the Netherlands. Eur J Surg Oncol 36:S100–S107. https://doi.org/10.1016/j.ejso.2010.06.003. (PMID: 10.1016/j.ejso.2010.06.00320598491)
Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Lin CC, Zietman AL et al (2013) Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol 63:823–829. https://doi.org/10.1016/j.eururo.2012.11.015. (PMID: 10.1016/j.eururo.2012.11.01523200811)
Jahnson S, Damm O, Hellsten S, Holmäng S, Liedberg F, Ljungberg B et al (2009) A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden. Scand J Urol Nephrol 43:271–276. https://doi.org/10.1080/00365590902909778. (PMID: 10.1080/0036559090290977819424934)
John JB, Varughese MA, Cooper N, Wong K, Hounsome L, Treece S et al (2020) Treatment allocation and survival in patients diagnosed with nonmetastatic muscle-invasive bladder cancer: an analysis of a National Patient Cohort in England. Eur Urol Focus. https://doi.org/10.1016/j.euf.2020.01.013. (PMID: 10.1016/j.euf.2020.01.01332088138)
Sobin LH, Gospodarowicz MK, Wittekind C (2010) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell.
Reesink DJ, van de Garde EMW, Somford DM, Meijer RP, Los M, Biesma DH et al (2021) Development of the first patient-centred set of outcomes for muscle-invasive and metastatic bladder cancer: a multicentre initiative. Eur Urol Open Sci 26:18–26. https://doi.org/10.1016/j.euros.2021.01.014. (PMID: 10.1016/j.euros.2021.01.014343375048317903)
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2008) New response evaluation criteria in solid tumours : Revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026. (PMID: 10.1016/j.ejca.2008.10.026)
Fonteyne V, Ost P, Bellmunt J, Droz JP, Mongiat-Artus P, Inman B et al (2018) Curative treatment for muscle invasive bladder cancer in elderly patients: a systematic review. Eur Urol 73:40–50. https://doi.org/10.1016/j.eururo.2017.03.019. (PMID: 10.1016/j.eururo.2017.03.01928478043)
Bos MK, Marmolejo RO, Rasch CRN, Pieters BR (2014) Bladder preservation with brachytherapy compared to cystectomy for T1–T3 muscle-invasive bladder cancer: A systematic review. J Contemp Brachytherapy 6:191–199. https://doi.org/10.5114/jcb.2014.43777. (PMID: 10.5114/jcb.2014.43777250975614105649)
Bajaj A, Martin B, Bhasin R, Hentz C, Block AM, Harkenrider MM et al (2018) The impact of academic facility type and case volume on survival in patients undergoing curative radiation therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 100:851–857. https://doi.org/10.1016/j.ijrobp.2017.11.040. (PMID: 10.1016/j.ijrobp.2017.11.04029485062)
Hermans TJN, Fransen van de Putte EE, Horenblas S, Meijer RP, Boormans JL, Aben KKH et al (2016) Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer—results of a nationwide population-based study. Eur J Cancer 69:1–8. https://doi.org/10.1016/j.ejca.2016.09.015. (PMID: 10.1016/j.ejca.2016.09.01527814469)
Hermans TJN, Voskuilen CS, Deelen M, Mertens LS, Horenblas S, Meijer RP et al (2019) Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer. Int J Cancer 144:1453–1459. https://doi.org/10.1002/ijc.31833. (PMID: 10.1002/ijc.3183330155893)
Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S et al (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55:241–252. https://doi.org/10.1016/j.critrevonc.2005.06.003. (PMID: 10.1016/j.critrevonc.2005.06.00316084735)
معلومات مُعتمدة: ML40374 Roche
فهرسة مساهمة: Investigator: DH Biesma; PEF Stijns; J Lavalaye; PC De Bruin; BJM Peters; M Berends; R Richardson; J Van Andel; OS Klaver; BCM Haberkorn; JM Van Rooijen; RA Korthorst; RP Meijer; JRN Van der Voort Van Zyp
Keywords: Bladder cancer; Metastatic; Muscle invasive; Outcomes; Treatment patterns
تواريخ الأحداث: Date Created: 20220410 Date Completed: 20220608 Latest Revision: 20220608
رمز التحديث: 20221213
DOI: 10.1007/s00345-022-03987-4
PMID: 35397692
قاعدة البيانات: MEDLINE
الوصف
تدمد:1433-8726
DOI:10.1007/s00345-022-03987-4